IRULYA THERAPEUTICS INC

Irulya Therapeutics’ stock falls 13.9%, yet its precision bone‑disease strategy and recent Rule 144 filing hint at long‑term growth potential—stay tuned for clinical updates.

Irulya Therapeutics drops 13.9% as investors re‑evaluate its high‑beta biotech valuation, spotlighting risks of unproven pipelines and thin liquidity.

Irulya Therapeutics climbs 16.9% as biotech outpaces peers—market cap $35M, bullish 200‑day SMA, and a precision bone‑regeneration platform poised for growth.